Managing diabetic macular edema (DME) remains a complex challenge for clinicians across India. While anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard of care, treatment response varies significantly among patients. Consequently, the integration of AI in DME treatment offers a promising shift from generalized protocols to personalized precision medicine. These advanced tools help clinicians navigate the high treatment burden and individualize risk stratification.

Enhancing Precision with AI in DME Treatment

Artificial intelligence systems leverage deep learning to identify subtle imaging biomarkers that the human eye might miss. These models analyze multimodal data, including fundus images and follow-up optical coherence tomography (OCT). By capturing statistical associations, AI can accurately classify likely responders before initiating therapy. Furthermore, these tools quantify imaging biomarkers to track disease progression over time. Therefore, clinicians can better predict central subfield thickness and vision outcomes after the initial loading doses.

AI-driven decision support also streamlines clinical workflow by integrating systemic data with local ocular findings. This comprehensive approach allows for tailored \"treat-and-extend\" intervals, reducing the cumulative treatment burden for patients. For example, systems may recommend switching to steroids or combination strategies when a poor response is predicted early. However, the medical community must still address issues like generalizability and ethical deployment. Despite these hurdles, AI-enabled support is becoming an essential component of modern ophthalmology.

Frequently Asked Questions

How does AI help in selecting the right DME treatment?

AI analyzes OCT images and clinical data to identify patterns associated with treatment response. This allows doctors to choose between different anti-VEGF agents or alternative therapies more effectively based on individual risk profiles.

Can AI predict the future injection burden for a patient?

Yes, advanced machine learning models can estimate the likely frequency of injections by evaluating baseline imaging and the initial response to loading doses, helping manage patient expectations and clinical resources.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Always consult with a qualified specialist regarding medical conditions. Refer to the latest local and national guidelines for clinical practice.

References

Ratra D et al. The evolving role of artificial intelligence in optimizing treatment and patient selection in diabetic macular edema. Indian J Ophthalmol. 2026 May 01. doi: 10.4103/IJO.IJO_3152_25. PMID: 42060353.

Chakroborty S, Gupta M, Devishamani CS, et al. Narrative review of artificial intelligence in diabetic macular edema: Diagnosis and predicting treatment response using optical coherence tomography. Indian J Ophthalmol. 2021 Nov;69(11):2999-3008.

Luvisi J et al. AI Model May Predict Anti-VEGF Treatment Response in Diabetic Macular Edema. American Academy of Ophthalmology (AAO). Published March 20, 2025.